secwatch.observer — SEC 8-K summary
======================================

Issuer:     enGene Therapeutics Inc. (ENGN)
CIK:        0001980845
Form:       8-K
Filed at:   2025-06-12T23:59:59+00:00
Accession:  0000950170-25-085138
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

enGene Q2 loss $25.8M ($0.51/shr); cash $251.5M; LEGEND study on track
----------------------------------------------------------------------

- Net loss $25.8M ($0.51/shr) vs $15.0M ($0.38) YoY; operating expenses $27.1M (up 57%).
- Cash and marketable securities $251.5M expected to fund operations into 2027.
- LEGEND pivotal cohort enrollment on track; BLA filing for detalimogene planned mid-2026.
- EMA indicates data could support Conditional Marketing Authorization for BCG-unresponsive NMIBC.
- Amy Pott appointed Chief Global Commercialization Officer effective May 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1980845/000095017025085138/0000950170-25-085138-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1980845/000095017025085138/engn-20250612.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-085138

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer